These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 9114205

  • 1. beta-Lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone.
    Williams JD.
    Clin Infect Dis; 1997 Mar; 24(3):494-7. PubMed ID: 9114205
    [Abstract] [Full Text] [Related]

  • 2. In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and beta-lactamase studies.
    Jones RN, Wilson HW, Thornsberry C, Barry AL.
    Diagn Microbiol Infect Dis; 1985 Nov; 3(6):489-99. PubMed ID: 2998694
    [Abstract] [Full Text] [Related]

  • 3. The cefoperazone-sulbactam combination. In vitro qualities including beta-lactamase stability, antimicrobial activity, and interpretive criteria for disk diffusion tests.
    Jones RN, Barry AL, Thornsberry C, Wilson HW.
    Am J Clin Pathol; 1985 Oct; 84(4):496-504. PubMed ID: 2994461
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S, Hanaki H, Nagayama A.
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vitro activity of cefoperazone/sulbactam and other antimicrobials against anaerobic bacteria.
    D'Amato RF, Hochstein L, Frankel H.
    Diagn Microbiol Infect Dis; 1990 Apr; 13(1):51-5. PubMed ID: 2331850
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In vitro activity of cefoperazone-sulbactam: Singapore experience.
    Kumarasinghe G, Chow C, Chiu C, Cheong YM.
    Southeast Asian J Trop Med Public Health; 1996 Dec; 27(4):734-7. PubMed ID: 9253876
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. In vitro activity of cefoperazone-sulbactam combinations against cefoperazone-resistant clinical bacterial isolates.
    Eliopoulos GM, Klimm K, Ferraro MJ, Moellering RC.
    Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):624-6. PubMed ID: 2506024
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS, Tosin I, Sejas L, Miranda E.
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [Abstract] [Full Text] [Related]

  • 20. [Synergy between sulbactam and ampicillin or cefoperazone in antimicrobial activity against beta-lactamase producing microorganisms. Results with the use of microdilution broth method].
    Deguchi K, Yokota N, Koguchi M, Nakane Y, Fukushima Y, Fukayama S, Ishihara R, Oda S, Tanaka S, Sato K.
    Jpn J Antibiot; 1990 Jul; 43(7):1214-24. PubMed ID: 2232151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.